## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity	
ATC Alloys Limited (Company)	
ABN	
88 118 738 999	

We (the entity) give ASX the following information.

+Class of +securities issued or to be

#### Part 1 - All issues

1

You must complete the relevant sections (attach sheets if there is not enough space).

2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

10 Notes

Convertible Notes (Notes)

Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

10 Notes with a Face Value of \$25,000 each convertible on or before 1 July 2018 (**Maturity Date**) at the lower of \$0.05 per share and the lowest issue price of any shares by the company prior to the Maturity Date and a coupon rate of 12% per annum

4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

The Notes do not rank equally with an existing class of security. The Notes do not carry any entitlement to participate in any dividends. All Shares issued upon their exercise will rank equally with all other fully paid ordinary shares on issue

5 Issue price or consideration

10 Notes at Face Value of \$25,000

6 Purpose of the issue
(If issued as consideration for the acquisition of assets, clearly identify those assets)

10 Notes at Face Value of \$25,000 issued to lenders

6a Is the entity an \*eligible entity that has obtained security holder approval under rule 7.1A?

If Yes, complete sections 6b – 6h *in* relation to the +securities the subject of this Appendix 3B, and comply with section 6i

6b The date the security holder resolution under rule 7.1A was passed

6c Number of \*securities issued without security holder approval under rule 7.1

6d Number of \*securities issued with security holder approval under rule 7.1A

res

16 December 2015

Nil

Nil

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of securities issued under an exception in rule 7.2	N/A	
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Remaining 7.1 capacity Remaining 7.1A capacit	
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	22 March 2016	
		Number	+Class
8	Number and *class of all *securities quoted on ASX ( <i>including</i> the securities in section 2 if applicable)	106,268,444	Ordinary Shares

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (*including* the securities in section 2 if applicable)

Number	+Class
2,791,431	Options exercisable
	at \$2,75 on or before
	27/11/2016
9,663,150	Options exercisable
	at \$0.75 on or before
	9/03/2017
300,000	Options exercisable
	at \$0.58 on or before
	31/07/2018
1,500,000	Options exercisable
	at \$0.75 on or before
	31/07/2019
35	Notes with a Face
	Value of \$50,000
	convertible at \$0.25 per share on or
	before 01/07/2018
2	Notes with a Face
_	Value of \$25,000
	convertible at \$0.25
	per share on or
	before 01/07/2018
23	Notes with a Face
	Value of \$50,000
	convertible at \$0.05 per share on or
	before 01/07/2018
6	Notes with a Face
	Value of \$20,000
	convertible at \$0.05
	per share on or before 01/07/2018
2	_
_	Notes with a Face Value of \$10,000
	Value of \$10,000 convertible at \$0.05
	per share on or
	before 01/07/2018
10	Notes with a Face
	Value of \$25,000
	convertible at \$0.05
	per share and the lowest issue price of
	any shares of the
	Company on or
	before 01/07/2018

	distribution policy) on the increased capital (interests)	
Part 2	? - Bonus issue or pro rata iss	ue N/A
11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	N/A
15	<sup>+</sup> Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has *security holders who will not be sent new issue documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A

Dividend policy (in the case of a trust, No dividend policy established

10

<sup>+</sup> See chapter 19 for defined terms.

### Appendix 3B

ew is	ew issue announcement			
20	Names of any underwriters	N/A		
21	Amount of any underwriting fee or commission	N/A		
22	Names of any brokers to the issue	N/A		
23	Fee or commission payable to the broker to the issue	N/A		
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	N/A		
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A		
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A		
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A		
28	Date rights trading will begin (if applicable)	N/A		
29	Date rights trading will end (if applicable)	N/A		
30	How do *security holders sell their entitlements <i>in full</i> through a broker?	N/A		
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A		
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	N/A		

<sup>+</sup>Despatch date

33

01/08/2012 Appendix 3B Page 6

N/A

<sup>+</sup> See chapter 19 for defined terms.

### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	(tick one	)
(a)		Securities described in Part 1
(b)		All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entitie	s that ha	ve ticked box 34(a)
Additi	ional sec	urities forming a new class of securities
	to indicate ments	you are providing the information or
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 100,000 10,001 - 100,000 100,001 and over

A copy of any trust deed for the additional \*securities

37

<sup>+</sup> See chapter 19 for defined terms.

Entities	Entities that have ticked box 34(b)			
38	Number of securities for which <sup>+</sup> quotation is sought			
39	Class of *securities for which quotation is sought			
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?  If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment			
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another security, clearly identify that other security)			
42	Number and +class of all +securities quoted on ASX (including the securities in clause 38)	Number	+Class	

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 22 March 2016 (Director/Company secretary)

Iohn Arbuckle

== == == ==

Print name:

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

### N/A

### Part 1

Rule 7.1 – Issues exceeding 15% of capital  Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Add the following:	
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	75,730,279
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval	6,218,729
Number of partly paid ordinary securities that became fully paid in that 12 month period	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil
"A"	106,268,444

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	15,940,267
Step 3: Calculate "C", the amount of plathat has already been used	acement capacity under rule 7.1
Insert number of equity securities issued or agreed to be issued in that 12 month period not counting those issued:	10 Notes convertible into 5,000,000 Shares
<ul> <li>Under an exception in rule 7.2</li> </ul>	
• Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	5,000,000
Step 4: Subtract "C" from ["A" x "B"] t capacity under rule 7.1	o calculate remaining placement
"A" x 0.15	15,940,267
Note: number must be same as shown in Step 2	
Subtract "C"	5,000,000
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.15] – "C"	10,940,267
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"  Note: number must be same as shown in Step 1 of Part 1	15,940,267	
Step 2: Calculate 10% of "A"		
"D"	0.10  Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10	1,594,027	
Step 3: Calculate "E", the amount of that has already been used	of placement capacity under rule 7.1A	
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	1,594,027	
Note: number must be same as shown in Step 2		
Subtract "E"	Nil	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	1,594,027	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.